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The Institute plans to hold a workshop this year to focus on the implications of HDFP for health research and health care, to assign priorities to some of these issues, and to investigate the feasibility of participation by other federal agencies in areas outside the usual domain of this Institute.
The HDFP went on during a period when we were already seeing a dramatic increase in attention to hypertension and a dramatic fall in stroke mortality. Nevertheless, the results of this study indicate that full application of what we already know about the treatment of hypertension, including mild hypertension, could save an additional 80,000-100,000 lives each year. Conclusion I have spent some time discussing Levy's arrow, using just one program as an example. I attempted to avoid belaboring you with statistics, number of projects supported in hypertension, budget allocations and funding mechanisms in order to focus on program needs and opportunities. We have needs in almost all the other program areas as well as opportunities just as exciting as those in hypertension. We are not opportunity-limited, but resource-limited. The key to the future of NHLBI and NIH, in seeking both the support of the Congress and the support of the general public, hinges on presenting the story of the NIH in terms of program achievements,opportunities and needs.
Coronary Bypass Surgery for Chronic Angina 1981
A Perspective SHAHBUDIN H. RAHIMTOOLA, M.D., F.R.C.P.
Life is short, and the art long; the occasion fleeting;
experience fallacious and judgement difficult.
-Hippocrates, Aphorisms CORONARY artery bypass graft surgery (CABG), available for the last 14 years, has been a most important advance in the management of symptomatic patients with coronary artery disease (CAD) . Medical and surgical therapy are complementary; patients treated surgically should also receive appropriate medical therapy.
Potential Problems in Evaluation of Data Medical Studies
The prognosis of patients with CAD treated by medical therapy has been studied often, but there have been no controlled studies of medical therapy. It is difficult to identify medically treated patients who could be compared with surgically treated patients because of differences in their conditions. Many of the medically treated patients were evaluated before 1970, and characterization of risk factors, ventricular function and even operability is often incomplete.'-' Moreover, medical therapy for angina in the 1970s is likely to be superior to that available in the 1950s and 1960s because of an increasing awareness of the need to con-them at high risk of death. The patients chosen for CABG are highly selected because usually they do not have other diseases that are likely to shorten their life.
Randomized Studies
Prospective randomized studies are believed to be of great value in the analysis of the results of a therapy. According to Feinstein,'7 the evidence of therapeutic benefit "is best obtained from well-designed controlled clinical trials in which the compared treatments have been assigned by randomization." A major advantage is that "it allows for separation of therapeutic effects from those that result from selection of patients."'8
However, randomized studies of CABG also have inherent problems. Large cooperative studies such as the Veterans Administration (VA) Cooperative Study'9 27 and the European Coronary Surgery Study (ECSS)28-30 involve many centers, and therefore have the potential problems of nonuniformity of patients, data acquisition and analysis, and treatment.-" The VA Cooperative Study had to recalculate some of their data, the quality of the angiographic studies is in some doubt, the quality of surgical results has been questioned, and there is also a problem of patient noncompliance with therapy.3" The VA Cooperative Study has generated a great deal of useful discussion. 7 , 18, 32-36f For several years the VA Cooperative Study was the only prospective randomized study that showed the superiority of CABG over medical therapy for improving survival in patients with disease of the left main coronary artery (LMCAD). It continues to provide a large amount of extremely useful information. 26' 27 In the ECSS, the interval between randomization to surgery was supposed to be 3 months or less; however, this goal was achieved in only 63% of patients. Six of the 21 deaths in the surgical group occurred preoperatively (29-82 days after randomization) and were included in the surgical mortality.29 In the VA Cooperative Study, 80 patients died between screening and randomization. 23 Randomized studies of CABG from a single center, e.g., the Houston VA Study37-40 and the University of Oregon Health Sciences Center,41 42 do not have many of the disadvantages of a large cooperative study. However, they are associated with other disadvantages, especially the small number of patients, which leads to three problems:
First, few patients are entered into the study each year from a large pool of patients seen at the medical center, or few patients were seen at the medical center.43 Therefore, there is a strong likelihood that patients were directed away from the study because of bias of the physicians at the medical center or of the referring physicians in the community. The first bias can be estimated by noting the number of patients who had CABG at the same medical center, but were not enrolled in the study. Refusal of the patient to participate in the study, particularly when the patient was presumably adequately informed about the marked variable. Thus, the patients evaluated may not be representative of the patients encountered in routine clinical practice. This criticism is valid for each hospital participating in a cooperative study.
Second, the small number of patients in such studies makes it probable that a "fl-type" error44 will be present in such data'3 because the study group is inhomogenous. An improvement with one form of therapy in the total group, and particularly in subgroups, may be missed by these small randomized studies. Third, small changes may influence statistical significance. For example, in the University of Oregon study, the incidence of all unstable angina in patients with two-vessel disease was significantly higher in the medical group than in the surgical group,43 but the next year this difference was no longer significant.'8 Perhaps only differences that achieve high statistical significance, i.e., the 1.0% or 0.1% level or greater, should be accepted as likely to be real.
Clearly, our task is to identify subgroups, based on invasive and noninvasive criteria, whose prognosis may be improved by CABG, because the impact of CABG on prognosis is not uniform for all subgroups and is probably negligible in some. Small randomized studies do not have enough patients for analysis of survival in subgroups and probably even in the total group. These disadvantages do not mean that small randomized studies are of no value. In a small randomized study of unstable angina in which the patients were evaluated for 4 months, no significant difference was demonstrated in mortality and myocardial infarction, but two-thirds of the medically treated patients continued to be significantly disabled and 45% subsequently required surgery.'6 47 The National Cooperative Study came to similar conclusions; admittedly, because more patients were studied, the confidence level in the results is higher and the National Cooperative Study has also provided other valuable data.'8 51 Thus, small randomized studies are of great value if the goals and the duration of the study are limited and if the differences that are sought between groups are large.
Another criticism of randomized studies is that they are often continued, for various reasons, long after it is clear that the questions posed have little or no chance of being answered.82 This is not always true, as studies have been stopped earlier than originally intended when it became clear that there was only a small chance of proving a hypothesis. 83 One major risk of prolonging such studies is that they may have more impact on clinical practice than they deserve.
Feinstein'7 suggested that the problems are produced by inadequacies in the design of large-scale clinical trials rather than in randomized studies. However, large-scale clinicals trials can be well designed, as exemplified by the Coronary Artery Surgery Study of the National, Heart, Lung, and Blood Institute.
Even the medically treated patients in the prospective randomized studies cannot be used in assessing symptomatic benefit with surgical therapy, is another 226 CIRCULATION survival with medical therapy because the patients ex-cluded from the study are not precisely documented; many patients cross over from the medical to the surgical group; and there are significant gaps in the documentation of clinical status, the nature of medical therapy and its success rate.
Results of Nonsurgical Therapy of CAD Early survival studies of patients with angina are of great historical interest but of limited value when assessing results of CABG.' 55 The Framingham study"6 has established the importance of various risk factors in the development of clinical coronary artery disease (smoking, hypertension, hyperlipedemia, diabetes, positive family history and male sex). Frank et al.57 reported a 4-5-year survival estimate of 82% after the first appearance of angina among 275 persons from the Health Insurance Plan of Greater New York. Kannel and Feinlieb, in the Framingham study,58 showed a 4-year survival rate of 85% for men with uncomplicated angina and 81% for men with angina and previous myocardial infarction. More recent data from Framingham"9" 60 showed that for survivors of myocardial infarction, the risk of death for men is 5% per year and for women 7% per year for the next 10 years; that remission of new angina for 2 years occurred in only 32% of the men, but in 44% of the women; and that transient and persistent angina have similar risk attributes but different prognoses. Men with transient angina had a 0% incidence of myocardial infarction and death in 4 years, whereas men with persistent angina had a 12% incidence of myocardial infarction and a 20% incidence of death in 4 years. Coronary arteriography was not performed in these community-based studies.
The survival of patients with CAD documented by coronary arteriography has been studied by many groups. Proudfit and co-workers8 showed that survival can be related to several clinical characteristics: severity and duration of angina, abnormalities on the ECG and heart size on the chest x-ray. McNeer and co-workers8 showed that data from exercise tests in patients with documented CAD can also be used to predict survival. The mortality of patients who achieved stage IV or greater of the Bruce protocol or who had a maximal heart rate > 160 beats/min was 1% at 1 year and 10% at 4 years. Patients who stopped in stage I had a mortality rate of 41% per year for 2 years and patients with a maximal heart rate < 120 beat/min had a mortality of 42% at 4 years. Using a combination of exercise variables, patients were subdivided into high-risk and low-risk subgroups8 (table 1).
Exertional hypotension described by Bruce and co-workers8' occurs in patients with multivessel coronary disease and has been attributed to ischemic left ventricular (LV) dysfunction.12-" The reported incidence of LMCAD with this abnormal hemodynamic response is 15-35%.68, 1 Although the prognostic significance of this finding is not clear,65' 67 some evidence suggests that it is associated with a greater incidence of subsequent cardiac death. 68 Freisinger and co-workers69" 70 first pointed out that survival is related to the extent of CAD. Since then, an important principle has been established and so far remains unchallenged: the more coronary arteries that are obstructed and the greater the degree of LV dysfunction, the worse the prognosis. For example, patients with two-vessel disease have a lower survival rate than those with one-vessel disease and a better survival rate than those with three-vessel disease. Patients with LMCAD have a high mortality rate. LMCAD is almost always accompanied by disease in either two or three of the major coronary arteries and is rarely found as an isolated lesion. Some data suggest that mortality of patients with LMCAD may be similar to that of patients with three-vessel disease;2' 71 however, recent prospective studies of LMCAD suggest that the prognosis of patients with LMCAD is worse than that of patients with threevessel disease.'0' 12, 21 Burggraf and Parker72 showed that the survival curve of patients with two-vessel disease became similar to that of three-vessel disease about 5-6 years after coronary arteriography. The most reasonable explanation is that in patients with two-vessel disease, the third coronary artery also becomes diseased. This serves to reemphasize that obstructive CAD (invariably the result of coronary atherosclerosis) is usually progressive.
LV function may be the most important determinant of survival in patients with CAD. In the study of Burggraf and Parker,72 angiographically abnormal LV function and an elevated LV end-diastolic pressure were associated with 5-year survival rates of 62% and 58%, respectively. In contrast, the 5-year survival of patients with normal hemodynamics and normal LV angiograms was 93%. Vlietstra and co-workers7 showed the 4-year survival rates of patients with LV ejection fraction 0.50 and 0.25-0.49 were 91% and 68%, respectively. Fourteen of 21 patients with ejection fraction of < 0.25 were dead within 2 years.
Even in patients with defined coronary anatomy and LV function, the suitability of the patient for surgery is also related to prognosis (table 2). For example, the data of Proudfit et al. 3 show that the 10-year survival of patients with three-vessel disease was 9% for those who were unsuitable for revascularization, 24% for those suitable for partial revascularization and 45% for those suitable for complete revascularization; that is, the patient likely to have the best survival with surgical treatment is also the patient likely to have the best survival with medical treatment.
Hammermeister and co-workers9 used 46 variables selected from clinical examination, exercise test, coronary arteriography and quantitative angiographic assessment of LV function to evaluate survival in 733 medically treated patients by univariate and multi-variate analyses. Their data supported LV function (ejection fraction) as the most predictive of survival. For ejection fractions of 0.51, 0.31-0.50 and < 0.30, the mortality rates were 22, 85 and 272 deaths/1000 man-years, respectively. Age, number of vessels with significant stenosis and ventricular arrhythmia on the resting ECG followed ejection fraction in importance of predicting survival. Patients with two-and three-vessel disease had mortality rates that were 3 and 5.5 times greater than the mortality rate of patients with one-vessel disease.
Harris et al.,12 using similar techniques, evaluated 57 noninvasive baseline clinical characteristics and 24 catheterization descriptors to evaluate survival in 1214 symptomatic, medically treated patients with documented CAD. Seven noninvasive characteristics and six invasive characteristics were independently significant. The annual mortality based on the extent of CAD and the state of LV function is shown in table 1. At the end of 1 and 5 years, the incidence of death was 8% and 22% and of myocardial infarction 6% and 14%, respectively. More recent data of Harris et al. 73 show that in patients with one-(n = 307), two-(n = 309), three-(n = 521) vessel disease and LMCAD (n = 77), the 5-year cardiac death rates were 6%, 14%, 30% and 61 %, respectively, and the 5-year incidence of nonfatal myocardial infarction was 12%, 14%, 16% and 9%, respectively. Among patients who had progressive chest pain, survival was decreased at almost all levels of vessel involvement and state of ventricular function compared with patients who had nonprogressive pain.'2' 73 Randomized studies of CABG for chronic angina 9-42 have shown that the survival of medically treated patients is better than would be predicted from nonrandomized studies. The average annual mortality is about 4% in patients with normal and abnormal LV function and one-, two-and three-vessel disease.
Left Main Coronary Artery Disease
LMCAD is a particularly lethal form of CAD. It occurs in about 5% of patients with chronic angina,74 7 7% of patients with a recent myocardial infarction,76 and 12% of patients with unstable angina.74 In two reports from the Coronary Artery Surgery Study, the incidence of LMCAD was 9% and 7%.77, 78 Isolated LMCAD is rare. 73 The survival of medically treated patients with LMCAD is complex. As a group, the 4and 6-year survival rates of such patients are 65% and 44%, respectively at 10 years the survival of inoperable patients was 0%, of medically treated but partially revascularizable patients 13%, and of patients suitable for complete revascularization 3 1% (table 2) . Conley et al.10 showed that the 3-year survival of patients with LMCAD was 66% with 50-70% stenosis and 37% with 2 70% stenosis. These investigators separated low-risk and highrisk subgroups on the basis of a history of heart failure, chest pain at rest, cardiomegaly on the chest x-ray and ST-T-wave abnormalities on the resting ECG. The high-risk group had 1-and 3-year survival rates of 68% and 25%, compared with 97% and 74%, respectively, in the low-risk group. A 3-year mortality of 26% does not make the latter subgroup a particularly low-risk subgroup; the same also applies to a 3-year mortality of 34% of patients with 50-70% obstruction of the left main coronary artery. Three-year survival of patients with LMCAD and disease of the right coronary artery is 62-65%, while that of patients without associated right coronary disease is 83-100%.",1 21 Campeau and co-workers'1 showed the We have argued that proximal left anterior descending and proximal left circumflex disease should not be considered as equivalent to LMCAD without proof. 80 In brief, left main equivalent disease may not be physiologically and prognostically equivalent to LMCAD, and patients with LMCAD are not sufficiently homogenous to permit meaningful comparisons with other patient groups. Zajtchuk et al.8' compared surgically treated LMCAD with left main equivalent disease and, on the basis of differences in operative mortality, graft patency and symptomatic improvement, concluded that left main equivalent disease could not be equated with LMCAD. Babb and co-workers82 demonstrated that the short-term prognosis of patients with left main equivalent disease is more benign than that of patients with LMCAD.
Has Medical Therapy for Angina Changed During the Last 10 Years?
We know more of the importance of the control of risk factors for CAD and also of myocardial ischemia. We have a better and wider choice of therapy for control of these and for control of complications of CAD; for example, arrhythmias and heart failure. Many cardiologists would define intensive or maximal medical therapy as one which provides 24-hour coverage with long-acting nitrates and a-blocking agents in doses that achieve good control of blood pressure and heart rate. Our understanding about the nitrate88' 86 and :-blocker therapy87 combined with the availability of long-acting drugs and the need for aggressive 24-hour therapy has profoundly changed the manner in which patients are managed with medical therapy. However, the nature and magnitude of our efforts and the resultant success rate are not documented; most medical studies provide almost no data. Even the prospective randomized studies of CABG, which are research studies, do not provide adequate documentation of the medical therapy provided and their success rate. Further, randomized studies provide almost no data about the clinical status of their patients before entry into the study. For example, the number of patients who had received medical therapy and the nature and duration of such therapy are not given. The Hypertension Detection and Follow-up Program investigated the effects of stepped care (systematic antihypertensive treatment program) of hypertension vs referred care (community medical therapy). Patients in the stepped-care program had better control of hypertension and a lower mortality than patients in the referred-care program.88' 89 If the results from this study can be applied to angina, there must be room for a great deal of improvement in our management of patients with angina and myocardial ischemia.
Results of Coronary Bypass Surgery

Relief of Symptoms
In prospective randomized studies,129' 37-48 CABG has reduced symptoms in 76-90% of patients; 33-55% of patients become asymptomatic. Five to 6% of patients deteriorate. The improvement in symptoms of surgically treated patients is statistically significant compared with medically treated patients (table 3) . Two points must be mentioned about these randomized studies: they compare combined surgical and medical therapy with medical therapy, and in many instances when patients were first entered into the study, they may already have been receiving medical therapy; thus, they may not be similar to other patients who received no medical therapy. Although medically treated patients also become less symptomatic, less than 10% of patients become asymptomatic. In the ECSS, 15% of the medically treated patients became asymptomatic; however, the majority of these asymptomatic patients had received surgery and were in the crossover group.29 Fifty percent or more of medically treated patients continue to be severely limited. The improvement of asymptomatic state in surgically treated patients can be objectively demon-strated37-42 by exercise stress testing, pacing tachycardia and by lactate extraction across the myocardium. The incidence of unstable angina was significantly higher in patients treated with medical therapy, 38 42 and multiple episodes were more frequent in the surgically treated group.40 Many more surgically treated patients have an uneventful course for as long as 7 years. 40 The VA Cooperative Study has demonstrated improvement in the symptomatic state that is related to vein graft patency (table 4) . Vein graft patency rates in the randomized studies are 69-77%.
In the nonrandomized studies, the percentage of patients who become asymptomatic or are improved is, in general, 10-30% higher. [90] [91] [92] [93] The improvement in symptomatic state has been shown to be related both to vein graft patency and to completeness of revascularization. Vein graft patency in these studies is generally 10-14% higher than in the randomized studies. Assad-Morell and co-workers9 showed that 80% of completely revascularized patients became asymptomatic and 91% had a negative treadmill exercise test; when one obstructed vessel was left ungrafted, 63% of patients became asymptomatic and 30% had a negative treadmill exercise test; and when two obstructed vessels were left ungrafted, 16% of patients became asymptomatic and 4% had a negative treadmill exercise test. At the time when most of the randomized patients underwent CABG, complete revascularization was not uniformly practiced. Thus, the symptomatic improvement of a higher percentage of patients in the nonrandomized studies may be related to higher vein graft patency rates and to a greater percentage of patients who were completely revascularized. In the ECSS, surgery was performed in many patients at a later time than in the other randomized studies.
Anderson et al. 92 showed that the relief of symptoms persists for many years; however, in some surgical patients, symptoms recur after the initial period of benefit. Campeau and co-workers93 showed the attrition rate may be as high as 4.4% per year for 6 years for the patient who is asymptomatic at the end of 1 year, and 2% per year for all patients who were improved at the end of 1 year. Data from New York98 showed a linear 3.5% annual recurrence rate of angina. The recurrence of symptoms is related to late development of obstruction and closure of vein grafts in 25% of patients and to progression of disease in native ungrafted arteries in 50% or to both in 25% of patients.98 Because more complete revascularization is now undertaken and vein graft patency rates are higher, recurrence of symptoms may occur with less frequency in patients operated on in the last 5-7 years.
Myocardial Infarction None of the pospective randomized studies have shown a reduction in myocardial infarction in surgically treated patients compared with medically treated patients. One reason for this is the occurrence of perioperative myocardial infarction in a high percentage of patients. The VA Houston prospective randomized study is showing a lower incidence of reinfarction in surgically treated patients compared with those treated medically after a median follow-up of 80 months. 40 The incidence of perioperative myocardial infarction has been drastically reduced with use of cold cardioplegia (and possibly also potassium arrest) for myocardial protection during surgery.97 More com plete myocardial revascularization has been performed in the last few years. Thus, the incidence of all myocardial infarction 3-5 years after surgery for patients operated on within the last 5 years may be lower.
Operative Mortality
The operative mortality in randomized studies has ranged from 4-5.6%. In nonrandomized studies, the operative mortality has ranged from 1-4%,9>9' although in some centers it has been much higher.20
Late Survival
Nonrandomized studies show that the late survival of CABG patients is remarkably good considering that they have severe CAD. On the basis of a 4-year follow-up, Anderson et al.92 showed that the survival of operated patients with three-vessel disease was similar to that of patients with two-vessel disease and was not significantly different from that of patients with one-vessel disease. This has been repeatedly confirmed by other studies.'6 Recent data from the VA Cooperative Study25' 26 also showed that surgery abolished the difference between the high-risk and low-risk subgroups." 11 74, 76, 101, 102 Survival in patients with LMCAD has also been shown to be extremely good.
Two small randomized studies failed to show a difference in survival between medically and surgically treated patients.37 42 As discussed, patients with angina have a wide range of clinical, arteriographic and ventricular function characteristics. Small randomized studies of about 50 patients in each of the medical and surgical groups contain a heterogeneous group of patients (LV ejection fraction ranged from 0.30-0.90 and patients had a mixture of one-, two-and threevessel disease), and the numbers of patients in any subgroups are very small.42 Therefore, the confidence that survival in the entire group and in subgroups is or is not prolonged, on the basis of their findings, is low. However, initial results from the large VA Cooperative Study also failed to show an improvement in survival in surgically treated patients.'9 Evidence from other prospective randomized studies shows that CABG prolongs survival in some subgroups of patients. Data from the VA Hines Medical Center,43' 103 which participated in the National VA Cooperative Study, showed that surgically treated patients had 4-and 6-year survival rates of 92% and 88%, which were significantly (p < 0.03) better than the 4-and 6-year survival rates of 75% and 65% among medically treated patients. The survival of the surgically treated patients in this study was similar to that in the entire VA Cooperative Study, but the survival of the medically treated patients in the VA Hines Study was much lower than in the entire VA Cooperative Study. There are at least two explanations for these findings. First, the medical therapy at the Hines VA was worse than that at other participating VA hospitals. Second, the Hines VA group randomized a subset of patients who were at higher risk than did most of the other participating VA hospitals. Since the cardiologists at the Hines VA are competent and there are no data on the medical therapy provided in the VA Cooperative Study, the second explanation is more likely to be the correct one. Thus, there are probably subgroups of patients who live longer with surgical therapy. The problem is identifying these patients preoperatively.
The ECSS29 data showed that the 2-year survival for 219 surgical patients with three-vessel disease was 95.9 ± 1.3% and for 188 medically treated patients with three-vessel disease was 89.9 + 2.2% (p < 0.05); the 95% confidence interval for the difference was 6 ± 5%. The "mortality rate for deviants from the surgical protocol (two of 11) compared with that for deviants from the medical protocol (two of 32) diminish survival difference." 29 In other words, the higher mortality of "'surgical" patients treated medically (18%) than the difference in survival between the two groups and also the statistical significance of the better survival of the surgical group. This is because in the ECSS, patients were left in the group to which they were assigned, even if they received the other therapy. For example, the "surgical" patient who did not receive surgery was left in the surgical group and the "medical" patient who received surgery was left in the medical group for analysis of survival data. Recent data from the ECSS showed the 5-year survival rates of medically and surgically treated patients with threevessel disease were 85% and 95%, respectively (p < 0.001).30 The difference in survival between the two forms of therapy averages 2% per year.
Takaro et al. analyzed the survival data of the subgroup of VA Cooperative Study patients from 10 hospitals in which the aggregate operative mortality was 3.4% and included 70% of the patients. In these 252 patients with three-vessel disease, the 6-year survival rates of surgically and medically treated patients were 80% and 65%, respectively (p < 0.025).27 The average difference in survival between the two forms of therapy is 2.5% per year.
The VA Cooperative Study has recently shown a better survival rate among surgically treated patients than among medically treated patients in other subgroups.25 26 These subgroups were identified by presence of ST depression on the resting ECG plus the presence of at least two of the following: New York Heart Association functional class III or IV, history of hypertension and history of myocardial infarction, or all three of the above without ECG changes. For all 218 patients, the 5-year survival rate was 83% for surgically treated patients and 62% for medically treated patients (p < 0.0005); for the 184 patients with LMCAD, the 5-year survival rates are 83% and 66%, respectively (p < 0.01).26 For 10 hospitals with low operative mortality rates, in all patients (n = 190), the 5-year survival rates of surgically and medically treated patients were 89% and 61%, respectively (p < 0.0005); for the 157 patients with LMCAD, the 5-year survival rates of surgically and medically treated patients were 90% and 64%, respectively (p < 0.0005).26 ST-segment depression on the resting ECG was a common finding with VA Cooperative Study and is a nonspecific electrocardiographic sign.
An earlier report from the VA Cooperative Study2l' 22 showed that among patients with LMCAD, those treated surgically had a 2-year survival of 87%, compared with 65% in those treated medically (p < 0.02). The improvement in survival of surgically treated patients was largely the result of improved survival in patients with LV dysfunction (85% survival with surgical treatment vs 59% survival with medical treatment at 2 years, p < 0.02). There were too few patients with normal LV function; therefore, the improved survival in this subgroup did not reach statistical significance. This raises an interesting question: Is there such a thing as inoperable LMCAD? The extent of LV dysfunction that makes patients with LMCAD inoperable is not defined. Also, in some 231 of "medical" patients treated surgically (6%) reduced patients it is not possible to insert a graft into the distal artery. However, because surgical technique is improving continually, there must be very few patients with LMCAD who can be considered inoperable. Recent data from the ECSS showed the 5-year survival rates of patients with LMCAD treated medically and surgically were 62% and 93%, respectively (p < 0.037).30
LV Function
Data from many studies show that resting LV function evaluated by LV end-diastolic pressure and LV ejection fraction shows no significant change after CABG when compared with preoperative values or when compared with medically treated patients in prospective, randomized studies.'"' This occurs even when the data from many studies are pooled. These studies consist of three subgroups of patients: those in whom ejection fraction remains unchanged, those in whom the ejection fraction has deteriorated, and those in whom the ejection fraction has improved. If ejection fraction is normal at rest, or is reduced because of previous myocardial infarction,105 there is no reason to expect an improvement with surgical therapy. The deterioration of ejection fraction seen in some patients is usually related to the occurrence of intervening myocardial infarction.'" Those in whom ejection fraction is improved must represent an improvement in LV function at rest. Such patients are not obvious when one examines group data, because the values in these patients are mixed up with those of patients who have shown no change or those who have deteriorated. However, other studies show an improvement in LV function with CABG and also in subgroups of patients with patent grafts.107`'09 Presumably, the mechanism of improvement of ventricular function at rest is relief of resting ischemia.
The challenge, then, is to recognize preoperatively patients in whom LV function will improve after CABG (i.e., to recognize patients who have resting myocardial ischemia). Although there is no way to identify these patients accurately preoperatively, data from other centers and from our laboratory"10-112 suggest that preoperative improvement of LV function with nitroglycerin may indicate patients in whom LV function will improve postoperatively (figs. 1 and 2). Presumably, nitroglycerin relieves the resting myocardial ischemia in such patients. Not only hypokinetic, but also some akinetic, segments improved with nitroglycerin and also by CABG (figs. I and 2). Thus, one must not conclude that a segment of myocardium is irretrievably damaged because it appears to be akinetic on the ventriculogram. The specificity, sensitivity and predictive accuracy of the test were only 76%, 65% and 70%, respectively; however, if LV wall segments improved with nitroglycerin, they had an 85% chance of improving with CABG.'26 Improved wall motion with CABG was associated with improvement of ejection fraction from 0.47 ± 0.03 to 0.57 ± 0.03 (p < 0.05). Postextrasystolic beats show the same magnitude of change in wall motion as with nitroglycerin,113' 114 and have been shown to relate to results of CABG . 111, 115, 116 However, the mechanisms of action for improved wall motion function are different. Nitroglycerin relieves ischemia; postextrasystolic beats increase fiber length and have a positive inotropic effect.
Studies using contrast ventriculographyll7 and radionuclide angiography"l6l I" have shown that in patients with CAD, LV ejection fraction decreases with exercise; this can be reversed in most instances by CABG,120 the response becoming normal in 68%. Myocardial ischemia with or without pain impairs myocardial systolic function, and exercise is known to produce myocardial ischemia. Thus, radionuclide angiography has confirmed that exercise-induced myocardial ischemia can be relieved by successful CABG, but did not illuminate the problem of identifying resting myocardial ischemia and reversible resting abnormalities of LV function. However, recent studies by Beller and co-workers'121 122 suggest that one may obtain this information from resting studies of 201T1. They showed that two-thirds of the persistent defects present on preoperative exercise and redistribution 201TI imaging were lessened after CABG,'22 which strongly supports the concept that myocardial ischemia occurs at rest and can be relieved by CABG. Successful CABG also reverses exertional hypotension," which is believed to be due to acute, severe, ischemic LV dysfunction. on the randomized studies in which most patients had surgery in the earlier years. Vein graft patency rates are lower in the randomized studies (69-77%). Vein graft patency is likely to be higher in the groups with more surgical experience; however, vein graft occlusion continues to occur. For example, data from the Cleveland Clinic'30 show that in 100 consecutive single vein graft insertions to the left anterior descending coronary artery in patients with one-vessel disease, the overall patency rate was 79%; the patency rate was 61% in patients who were symptomatic when restudied, and even in the asymptomatic patients who were electively restudied, the vein graft patency rate was 91%. Thus, a 10-15% vein graft occlusion rate might be expected. Because vein graft patency is related to an improvement in the symptomatic state and possibly also to an improvement in LV function, any maneuver that improves vein graft patency rate is desirable. Pantely et al.53 evaluated the role of anticoagulant and antiplatelet therapy, starting 3 days after CABG, in the prevention of vein graft occlusion. There was no significant difference in the overall vein graft patency rate, in the numbers of patients having all patent grafts, and in those having at least one patent graft between these two treated groups and a control group who received placebo therapy. All patients had at least one patent graft; 64% of patients had all grafts patent. The vein graft patency rate was 92% for the left anterior descending/diagonal system, 80% for the right coronary artery and 69% for the obtuse marginal coronary artery. When the data from all three subgroups were combined, the patency rate of grafts to the obtuse marginal coronary artery was significantly lower than the patency rate of grafts to the left anterior descending and the right coronary arteries. This study suggests that the major factors contributing to occlusion of vein grafts were the size of the grafted artery (the lowest incidence is in the left anterior descending coronary artery), the extent of disease in the distal vessel (and the resultant graft flow) and technical factorsnone of which were greatly modified by the medications.
The patency rate of left internal mammary artery grafts is about 95%.131 Most of these grafts are to the left anterior descending coronary artery, which is the largest coronary artery to which a graft is placed; therefore, a higher patency rate can be expected with any graft placed into this coronary artery. Saphenous vein grafts to the left anterior descending coronary artery have a 92% patency rate,58 which may not be significantly different from that with internal mammary grafts. Saphenous vein grafts have the capability of higher flow;'32'134 Loop et al. suggested that if a single graft to the left coronary artery is to be done in LMCAD, "4a single internal mammary artery graft should not be relied on to support the entire left coronary circulation."184 It is possible that the internal mammary graft is used when the left anterior descending coronary artery is small. Clearly, there is bias in selection of the internal mammary artery or saphenous vein in bypassing the obstructed coronary artery by surgeons who use both; thus, patency rates of saphenous vein and internal mammary grafts cannot be compared in these series.
Changes in Coronary Bypass Surgery
During the Last 10 Years Recent studies suggest that CABG has changed significantly during the last decade.
Operative Mortality
The operative mortality in three different studies has decreased significantly from 1967-1979.19' 135, 136 The operative mortality at the Cleveland Clinic99 was 3% from 1967-1980 and since then has been consistently less than 2%. Overall operative mortality for the 11 years was 1.1% and for 1971-1978 was 0.9%. At the University of Alabama,"'3 the operative mortality for isolated CABG for 1970-1973 was 2.7% and for 1974-1977 was 1.2%. For these two periods, the operative mortality rates in patients with one-vessel disease were 1.5% and 0.6%, with two-vessel disease 1.5% and 0.5%, for three-vessel disease 3.6% and 1.4%, and for LMCAD 6.1% and 1.7%, respectively. At
Portland, Oregon,'36 the operative mortality for the years 1969-1973 was 3.9% and 1.3% for years 1974-1979; the operative mortality by the number of coronary arteries involved and the state of LV function is shown in detail in table 5 and ranged from 0-3.5% Y. Age is also an important factor that affects operative mortality. In patients younger than 45 years, the operative mortality rates in the two periods were 5.1% and 0%, for those aged 46-65 years 3.6% and 1.3%, and for those older than 65 years 3.3% and 2.0%. In these three studies, the operative mortality has decreased even though the number of patients with three-vessel disease has increased. At Portland, the average age of the patients who underwent CABG was higher and the incidence of LV dysfunction was not significantly different in the two time periods. The decrease in operative mortality is also substantiated by the Coronary Artery Surgery Study.'37 In the 15 centers participating in this study, including 6630 patients that underwent operation between August 1975 and December 1978,137 the overall operative mortality was 2.3% (range 0.3-6.4%). Operative mortality increased with age, and was higher in women and in those with clinical manifestations of congestive heart failure. Mortality was 1.4% in one-, 2.1% in twoand 2.8% in three-vessel disease. Operative mortality rates were 1.9% and 6.7% for patients with ejection fraction . 0.50 and < 0.19, respectively. Operative mortality for elective surgery was 1.7%, for urgent surgery 3.5% and for emergency surgery 6.1%. In patients with LMCAD,78 the average operative mortality was 4.4% (range 0-28%). This mortality compares with 4.4% at the Cleveland Clinic,146 3% at the University of Alabama,'"6 and 2.5% at Portland, Oregon.'36 Two of the centers in the cooperative study had a 0% operative mortality in 53 operated patients, and the operative mortality in the seven centers with the lowest operative mortality was less than 2% (eight deaths among 416 patients). Before 1972, reported operative mortality from other centers was 14-29% and after 1972 was 2-15%.' The Coronary Artery Surgery Study also shows that even in the late 1970s, operative mortality varies among the various institutions. 78, 137 Perioperative Myocardial Infarction At the University of Alabama,'35 the perioperative myocardial infarction rate has decreased from 11.4% to 2.4%. At the Cleveland Clinic,'12 the perioperative myocardial infarction rate has decreased from 7.1% to 1.2%. These values are probably lower than the true incidence of perioperative myocardial damage because radionuclide techniques were not used to evaluate myocardial infarction.'"8 138 1969-1973, the percentages of patients with one, two and three or more diseased vessels were 23%, 39%O and 38% and the percentages of patients with one, two and three or more grafts were 41%, 44% and 15%, respectively. For the period 1974-1979, the percentages of patients with one, two and three or more diseased vessels were 16%, 28% and 56%, respectively; the percentages of patients with one, two and three or more grafts were 21%, 36% and 43%, respectively.
Late Survival
Loop and co-workers99 evaluated the long-term survival among patients who underwent CABG between 1967 and 1970 and compared this with the first 1000 patients who underwent CABG during 1971 . From 1967 -1970 exi improved care of the patient and the myocardium during and after operation and more complete myocardial revascularization.'36 Once again, the effects of improved medical therapy in these patients are difficult to document.
It is reasonable to conclude from these data that CABG in the second half of the last decade was different from that in the first half. Although older patients and patients with more extensive coronary artery disease underwent CABG, the operative mortality had decreased, the incidence of perioperative myocardial infarction was lower, more complete revascularization was being performed, and the late survival rate of patients was better. CABG underwent many changes in the last decade; the results in patients who underwent CABG during the second half of the last decade are superior to those in patients who underwent CABG during the first half of the decade. Therefore, the expected beneficial effects of CABG will be underestimated if based on data in patients who underwent operation in the first half of the last decade."0 Hippocrates' aphorism is relevant to CABG for riods were 88.9% and 92.5% (p = 0.006) ( fig. 3 ). The angina in 1981; one has to have an open and receptive
year survival rates for patients who underwent mind and a balanced view. CAD and CABG are com-LBG from 1974-1979 (1969-1973) were 98% (95%), plex, multifaceted problems; no single study will % (9 1%), 93% (92%) and 97% (86%) in patients with provide all the answers. Data from randomized and rmal LV function and one-, two-and three-vessel nonrandomized studies must be evaluated and judgsease and LMCAD; for patients with abnormal LV ments made. nction and one-, two-, three-vessel disease and
The management of patients with angina has to be qCAD, the 4-year survival rates were 93% (88%), individualized based on the needs and expectations of % (86%), 84% (80%) and 91% (46%), respectively. the patient and realistic expectations based on the ie 4-year survival in the latter cohort was usually results of medical therapy and of CABG. The demontter than in those operated on in the earlier period, strated results of medical therapy in the second half of rticularly for patients with abnormal LV function.
the last decade are not known, although considerable ie improved 4-year survival resulted from reduced advances have been made in the use of nitrate and fierative mortality, the long-term beneficial effect of blocker therapy. All In subgroups other than those noted above, life may 70s, even though these patients were older and had more be prolonged; the problem is to identify these with tensive coronary artery disease."3 confidence preoperatively. For the last few years, our Other Survival prolonged in other subgroups.43 103 LV function improved in some subgroups. Challenge is to accurately describe these subgroups preoperatively. *A 0% operative mortality means the operative mortality is very low but will not necessarily be 0% as more patients are operated.
Abbreviations: LMCAD = left main coronary artery disease; NYHA = New York Heart Association; MI = myocardial infarction; LV = left ventricular; CAD = coronary artery disease; LAD = left anterior descending coronary artery; RCA = right coronary artery; OM = obtuse marginal coronary artery. task has been to identify subgroups, based on invasive and noninvasive criteria, whose prognosis may be improved by CABG because the impact of CABG on prognosis is not uniform for all subgroups and is probably negligible in some.
Although excellent results of CABG are reported throughout the U.S. and abroad, in some institutions, the risks of CABG are higher. This must also be taken into account in deciding to recommend CABG to an individual patient. CABG for Chronic Angina CABG should be recommended for patients with LMCAD; three-vessel CAD; ST depression on the ECG plus at least two of the following: history of hypertension, history of myocardial infarction and New York Heart Association functional class III or IV, or all three of those with ECG changes; functional class III angina that does not respond rapidly and satisfactorily with appropriate medical therapy; and functional class II angina in a variety of clinical circumstances. If angina or medical therapy results in a restriction of working capacity or an undesirable change in lifestyle, then CABG should not be delayed. CABG should be seriously considered for patients Male 
